Related references
Note: Only part of the references are listed.Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects
Anette Sundstedt et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma
D. M. Shaw et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
RW Griffiths et al.
BRITISH JOURNAL OF CANCER (2005)
Interplay between superantigens and immunoreceptors
K Petersson et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2004)
Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose Control in PNU-214936
JD Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Identification of the antigenic epitopes in Staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy
E Erlandsson et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Ligand-targeted therapeutics in anticancer therapy
TM Allen
NATURE REVIEWS CANCER (2002)
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
G Forsberg et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
